BFM
BEAM icon

Boothbay Fund Management’s Beam Therapeutics BEAM Stock Holding History

Boothbay Fund Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-394
Closed -$3.15M – 1846
2021
Q1 		$3.15M Buy
394
+152
+63% +$14.5K 0.12% 190
2020
Q4 		$1.98M Buy
+242
New +$11.9K 0.07% 270

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Boothbay Fund Management's BEAM Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 15,027 shares worth $516K. The stake represents 0.01% of the portfolio and ranks #1476 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in BEAM as recently as Q4 2025.

Boothbay Fund Management first reported a position in BEAM in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.68M in Q4 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Boothbay Fund Management held 15,027 shares of Beam Therapeutics worth $516K as of Q2 2026.
  • Beam Therapeutics was a new Boothbay Fund Management position in Q2 2026.
  • Beam Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1476 holding.
  • Boothbay Fund Management first reported a position in Beam Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Boothbay Fund Management's Beam Therapeutics position peaked at $1.68M in Q4 2025.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.